
Sweden Diabetes Market, Size, Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis
Description
Sweden Diabetes Market, Size, Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis
Sweden's Diabetes Market will reach US$ 1.86 Billion in 2028 and expand at a CAGR of 4.26% from 2023 to 2028, according to Renub Research. Diabetes is obtaining epidemic proportions, and digital health companies are fighting back with innovative solutions. According to World Diabetes Organization, diabetes presently affects 59.8 million individuals in Europe, which will rise to 73.8 million by 2040. Diabetes is currently one of the most critical emergencies in global health and shows an increasing prevalence in Sweden. The healthcare system of Sweden has taken a heavy toll due to diabetes, which could be due to the associated direct costs required for medical management. Nowadays, caring for people with Type 2 diabetes has expanded from including only GPs to involving RNs in the main workforce. In Sweden, PHCCs have diabetes-responsible GPs and RNs available in-house who have the overall responsibility for the care and treatment of people with T2DM. According to Renub Research, the Sweden Market was US$ 1.45 Billion in 2022.
Type 2 diabetes is a heterogeneous disease in Sweden
Diabetes mellitus is recognized as an epidemic. The prevalence of type 2 diabetes is increasing dramatically in Sweden, with projections of even higher growth over the coming decades. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure are indications of the increasing usage of diabetic drugs. At any age, increasing weight raises the risk of type 2 diabetes. In people who are obese, type 2 diabetes is three to ten times more common than it is in people of average weight. Moreover, over the past decades, childhood-onset type 1 diabetes has been reported to be increasing in Sweden.
Insulin Pen will grow at a High Rate and Capturing the Highest Market Share in the Coming Years
The Sweden Diabetes Market by the device is segmented into; SMBG, CGM, Insulin Pumps, and Insulin Pens. Insulin cartridges in reusable pens are an upgraded version of insulin vials. Significant types of insulin are manufactured in the form of cartridges, which makes them easily attainable. These devices have all the functional advantages of reusable pens and are economical, as these cartridges are less costly than disposable insulin pens in the long run. Due to the rising demand for insulin cartridges, most insulin device manufacturers have produced reusable insulin pens compatible with various manufacturers' cartridges. These insulin cartridges are more consumer-friendly, as they are smaller and less observable than the classic vial-and-syringe. These devices are also more portable for consumers on the go.
Moreover, the SMBG segment also holds a significant market share. Driving factors that help to reach this market are the increasing diabetic population in Sweden, Governments, and NGOs' efforts to increase awareness, increasing per capita healthcare expenditure, and availability of reimbursements.
Key Players:
The major players competing in the Sweden Diabetes Market are B. Braun Melsungen AG, Eli Lilly and Company, Terumo Corporation, Becton, Dickenson (BD), Novo Nordisk A/S, Ypsomed AG, Medtronic, Insulet Corporation, Abbott Laboratories, DarioHealth Corp., Dexcom Inc., Roche Diagnostic, and Tandem Diabetes Care.
In May 2021, Medtronic announced the CE Mark for expanded functionality of the company's In Pen smart insulin pen for multiple daily injections (MDI).
In May 2021, Medtronic secured European approvals for its Guardian 4 sensor. The Guardian 4 sensor can be either utilized as a standalone continuous glucose monitor or combined into Medtronic's insulin pumps and pens to add real-time glucose monitoring alongside insulin tracking.
Renub Research report titled “Sweden Diabetes Market & Forecast, By Continuous Glucose Monitoring (CGM Market by Components, Glucose Sensor, Transmitter, CGM User, Reimbursement), Self-Monitoring Blood Glucose (SMBG Market by, Test Strips, Lancet, Meter, Blood Glucose Device Users & Reimbursement), Insulin Pen (User, Types – Disposable, Reusable and Smart Insulin Pen, Insulin Pen Needle Market, Reimbursement Policies), Insulin Pump (Users, Market & Differentiation Points of Insulin Pump Products, Training Model for Patients & HCP, Reimbursement Policies), Company (B. Braun Melsungen AG, Eli Lilly and Company, Terumo Corporation, Becton, Dickinson (BD), Novo Nardisk, Ypsomed AG, Medtronic, InsuletCorporation, Abbott Laboratories, DarioHealth Crop, Dexcom, Inc, Roche Diagnostic, Tandem Diabetes Care)” provides a complete analysis of Sweden Diabetes Industry.
Segments Market based on Devices
1. Continuous Glucose Monitoring (CGM)
2. Self-Monitoring Blood Glucose (SMBG)
3. Insulin Pen
4. Insulin Pump
Sweden Diabetes Sub-Segment Analysis
1. Continuous Glucose Monitoring (CGM)
1. Glucose Sensor Market & Forecast
2. CGM Transmitter Market & Forecast
3. CGM User
4. CGM Reimbursement
2. SMBG
1. Test Strips Market and Forecast
2. Lancet Market and Forecast
3. Meter Market and Forecast
4. Blood Glucose (SMBG) Users
5. Blood Glucose Devices Reimbursement
3. Insulin Pen Market
1. Disposable Insulin Pen
2. Reusable Insulin Pen
3. Smart Insulin Pen
4. Insulin Pen Needle Market
5. Insulin Pen Users
6. Reimbursement Policies
4. Insulin Pump Market
1. Insulin Pump Market
2. Insulin Pump Users
3. Insulin Pump Products
4. Reimbursement Policies
All the 13 Companies Studied in the Report have been Studied from 3 Points
• Company Overview
• Recent Developments
• Financial Insight
Company Analysis
1. B. Braun Melsungen AG
2. Eli Lilly and Company
3. Terumo Corporation
4. Becton, Dickinson (BD)
5. Novo Nardisk
6. Ypsomed AG
7. Medtronic
8. InsuletCororation
9. Abbott Laboratories
10. DarioHealth Crop
11. Dexcom, Inc
12. Roche Diagnostic
13. Tandem Diabetes Care
Sweden's Diabetes Market will reach US$ 1.86 Billion in 2028 and expand at a CAGR of 4.26% from 2023 to 2028, according to Renub Research. Diabetes is obtaining epidemic proportions, and digital health companies are fighting back with innovative solutions. According to World Diabetes Organization, diabetes presently affects 59.8 million individuals in Europe, which will rise to 73.8 million by 2040. Diabetes is currently one of the most critical emergencies in global health and shows an increasing prevalence in Sweden. The healthcare system of Sweden has taken a heavy toll due to diabetes, which could be due to the associated direct costs required for medical management. Nowadays, caring for people with Type 2 diabetes has expanded from including only GPs to involving RNs in the main workforce. In Sweden, PHCCs have diabetes-responsible GPs and RNs available in-house who have the overall responsibility for the care and treatment of people with T2DM. According to Renub Research, the Sweden Market was US$ 1.45 Billion in 2022.
Type 2 diabetes is a heterogeneous disease in Sweden
Diabetes mellitus is recognized as an epidemic. The prevalence of type 2 diabetes is increasing dramatically in Sweden, with projections of even higher growth over the coming decades. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure are indications of the increasing usage of diabetic drugs. At any age, increasing weight raises the risk of type 2 diabetes. In people who are obese, type 2 diabetes is three to ten times more common than it is in people of average weight. Moreover, over the past decades, childhood-onset type 1 diabetes has been reported to be increasing in Sweden.
Insulin Pen will grow at a High Rate and Capturing the Highest Market Share in the Coming Years
The Sweden Diabetes Market by the device is segmented into; SMBG, CGM, Insulin Pumps, and Insulin Pens. Insulin cartridges in reusable pens are an upgraded version of insulin vials. Significant types of insulin are manufactured in the form of cartridges, which makes them easily attainable. These devices have all the functional advantages of reusable pens and are economical, as these cartridges are less costly than disposable insulin pens in the long run. Due to the rising demand for insulin cartridges, most insulin device manufacturers have produced reusable insulin pens compatible with various manufacturers' cartridges. These insulin cartridges are more consumer-friendly, as they are smaller and less observable than the classic vial-and-syringe. These devices are also more portable for consumers on the go.
Moreover, the SMBG segment also holds a significant market share. Driving factors that help to reach this market are the increasing diabetic population in Sweden, Governments, and NGOs' efforts to increase awareness, increasing per capita healthcare expenditure, and availability of reimbursements.
Key Players:
The major players competing in the Sweden Diabetes Market are B. Braun Melsungen AG, Eli Lilly and Company, Terumo Corporation, Becton, Dickenson (BD), Novo Nordisk A/S, Ypsomed AG, Medtronic, Insulet Corporation, Abbott Laboratories, DarioHealth Corp., Dexcom Inc., Roche Diagnostic, and Tandem Diabetes Care.
In May 2021, Medtronic announced the CE Mark for expanded functionality of the company's In Pen smart insulin pen for multiple daily injections (MDI).
In May 2021, Medtronic secured European approvals for its Guardian 4 sensor. The Guardian 4 sensor can be either utilized as a standalone continuous glucose monitor or combined into Medtronic's insulin pumps and pens to add real-time glucose monitoring alongside insulin tracking.
Renub Research report titled “Sweden Diabetes Market & Forecast, By Continuous Glucose Monitoring (CGM Market by Components, Glucose Sensor, Transmitter, CGM User, Reimbursement), Self-Monitoring Blood Glucose (SMBG Market by, Test Strips, Lancet, Meter, Blood Glucose Device Users & Reimbursement), Insulin Pen (User, Types – Disposable, Reusable and Smart Insulin Pen, Insulin Pen Needle Market, Reimbursement Policies), Insulin Pump (Users, Market & Differentiation Points of Insulin Pump Products, Training Model for Patients & HCP, Reimbursement Policies), Company (B. Braun Melsungen AG, Eli Lilly and Company, Terumo Corporation, Becton, Dickinson (BD), Novo Nardisk, Ypsomed AG, Medtronic, InsuletCorporation, Abbott Laboratories, DarioHealth Crop, Dexcom, Inc, Roche Diagnostic, Tandem Diabetes Care)” provides a complete analysis of Sweden Diabetes Industry.
Segments Market based on Devices
1. Continuous Glucose Monitoring (CGM)
2. Self-Monitoring Blood Glucose (SMBG)
3. Insulin Pen
4. Insulin Pump
Sweden Diabetes Sub-Segment Analysis
1. Continuous Glucose Monitoring (CGM)
1. Glucose Sensor Market & Forecast
2. CGM Transmitter Market & Forecast
3. CGM User
4. CGM Reimbursement
2. SMBG
1. Test Strips Market and Forecast
2. Lancet Market and Forecast
3. Meter Market and Forecast
4. Blood Glucose (SMBG) Users
5. Blood Glucose Devices Reimbursement
3. Insulin Pen Market
1. Disposable Insulin Pen
2. Reusable Insulin Pen
3. Smart Insulin Pen
4. Insulin Pen Needle Market
5. Insulin Pen Users
6. Reimbursement Policies
4. Insulin Pump Market
1. Insulin Pump Market
2. Insulin Pump Users
3. Insulin Pump Products
4. Reimbursement Policies
All the 13 Companies Studied in the Report have been Studied from 3 Points
• Company Overview
• Recent Developments
• Financial Insight
Company Analysis
1. B. Braun Melsungen AG
2. Eli Lilly and Company
3. Terumo Corporation
4. Becton, Dickinson (BD)
5. Novo Nardisk
6. Ypsomed AG
7. Medtronic
8. InsuletCororation
9. Abbott Laboratories
10. DarioHealth Crop
11. Dexcom, Inc
12. Roche Diagnostic
13. Tandem Diabetes Care
Table of Contents
190 Pages
- 1. Introduction
- 2. Research & Methodology
- 3. Executive Summary
- 4. Market Dynamics
- 4.1 Growth Drivers
- 4.2 Challenges
- 5. Sweden Diabetes Market
- 6. Sweden Diabetes Population
- 6.1 Type 1 Diabetes
- 6.2 Type 2 Diabetes
- 7. Sweden Diabetes Market Share Analysis
- 7.1 By Types
- 8. Continuous Glucose Monitoring Market (CGM) – Market & Users
- 8.1 Sweden - CGM Market by Components
- 8.1.1 Glucose Sensor Market
- 8.1.2 CGM Transmitter Market
- 8.2 CGM User
- 8.3 Reimbursement Policies of CGM Devices in Sweden
- 9. Blood Glucose Device (SMBG) –Sweden Market & Users
- 9.1 Market
- 9.1.1 Type 1 Diabetes Market
- 9.1.2 Type 2 Diabetes Market
- 9.2 Test Strips Market
- 9.2.1 Type 1 Diabetes
- 9.2.2 Type 2 Diabetes
- 9.3 Lancet Market
- 9.3.1 Type 1 Diabetes
- 9.3.2 Type 2 Diabetes
- 9.4 Meter Market
- 9.4.1 Type 1 Diabetes
- 9.4.2 Type 2 Diabetes
- 9.5 Blood Glucose (SMBG) Users
- 9.5.1 Type 1 Diabetes
- 9.5.2 Type 2 Diabetes
- 9.6 Reimbursement Policies of Blood Glucose Devices in Sweden
- 10. Insulin Pen –Sweden Market & User Analysis
- 10.1 Insulin Pen Market
- 10.1.1 Disposable Insulin Pen Market
- 10.1.2 Reusable Insulin Pen Market
- 10.1.3 Smart Insulin Pen Market
- 10.2 Insulin Pen Needle Market
- 10.3 Insulin Pen User
- 10.3.1 Disposable Insulin Pen User
- 10.3.2 Reusable Insulin Pen User
- 10.3.3 Smart Insulin Pen User
- 10.4 Reimbursement Policies of Insulin Pen in Sweden
- 11. Insulin Pump – Sweden Market & Users
- 11.1 Insulin Pump Market
- 11.1.1 Type 1 Diabetes Market
- 11.1.2 Type 2 Diabetes Market
- 11.2 Insulin Pump User
- 11.2.1 Type 1 Insulin Pump User
- 11.2.2 Type 2 Insulin Pump User
- 11.3 Differentiation Points of Insulin Pump Products in Sweden
- 11.3.1 Animas Vibe
- 11.3.2 Medtronic 530G with Enlite
- 11.3.3 Insulet OmniPod
- 11.3.4 Tandem t: slim
- 11.3.5 Roche Accu-Chek Combo
- 11.4 Training Model for Patients & HCP – of Medtronic, Animas, Insulet Corp & Tandem Diabetes Care
- 11.4.1 Medtronic
- 11.4.1.1 Training Guidelines for Insulin Pump Therapy to New Patients
- 11.4.1.2 Training Model for HCP (HealthCare Professional)
- 11.5 Insulet Corporation
- 11.5.1 Training Structure for New Patients - Insulet Corporation
- 11.6 Animas Corporation
- 11.6.1 Training Modules for New Patients
- 11.6.2 Training Modules for HCP (Health Care Professional)
- 11.7 Tandem Diabetes Care
- 11.8 Reimbursement Policies Insulin Pump
- 12. Insulin Pen – Company Analysis
- 12.1 B. Braun Melsungen AG
- 12.1.1 Overview
- 12.1.2 Recent Developments
- 12.1.3 Revenue
- 12.2 Eli Lilly
- 12.2.1 Overview
- 12.2.2 Recent Developments
- 12.2.3 Revenue
- 12.3 Terumo Corporation
- 12.3.1 Overview
- 12.3.2 Recent Developments
- 12.3.3 Revenue
- 12.4 BD
- 12.4.1 Overview
- 12.4.2 Recent Developments
- 12.4.3 Revenue
- 12.5 Novo Nordisk A/S
- 12.5.1 Overview
- 12.5.2 Recent Developments
- 12.5.3 Revenue
- 12.6 Ypsomed AG
- 12.6.1 Overview
- 12.6.2 Recent Developments
- 12.6.3 Revenue
- 13. Insulin Pump – Company Analysis
- 13.1 Medtronic
- 13.1.1 Overview
- 13.1.2 Recent Developments
- 13.1.3 Revenue
- 13.2 Insulet Corporation
- 13.2.1 Overview
- 13.2.2 Recent Developments
- 13.2.3 Revenue
- 14. SMBG – Company Analysis
- 14.1 DarioHealth Corp
- 14.1.1 Overview
- 14.1.2 Recent Developments
- 14.1.3 Revenue
- 14.2 Abbott Laboratories
- 14.2.1 Overview
- 14.2.2 Recent Developments
- 14.2.3 Revenue
- 15. CGM – Company Analysis
- 15.1 Dexcom Inc
- 15.1.1 Overview
- 15.1.2 Recent Developments
- 15.1.3 Revenue
- 15.2 Roche
- 15.2.1 Overview
- 15.2.2 Recent Developments
- 15.2.3 Revenue
- 15.3 Tandem Diabetes Care
- 15.3.1 Overview
- 15.3.2 Recent Developments
- 15.3.3 Revenue
- List of Figures:
- Figure-01: Sweden – Diabetes Market (Billion US$), 2017 – 2022
- Figure-02: Sweden – Forecast for Diabetes Market (Billion US$), 2023 – 2028
- Figure-03: Sweden – Type 1 Diabetes Population (Thousand), 2017 – 2022
- Figure-04: Sweden – Forecast for Type 1 Diabetes Population (Thousand), 2023 – 2028
- Figure-05: Sweden – Type 2 Diabetes Population (Thousand), 2017 – 2022
- Figure-06: Sweden – Forecast for Type 2 Diabetes Population (Thousand), 2023 – 2028
- Figure-07: Sweden – Glucose Sensor Market (Million US$), 2017 – 2023
- Figure-08: Sweden – Forecast for Glucose Sensor Market (Million US$), 2023 – 2028
- Figure-09: Sweden – CGM Transmitter Market (Million US$), 2017 – 2023
- Figure-10: Sweden – Forecast for CGM Transmitter Market (Million US$), 2023 – 2028
- Figure-11: Sweden – CGM User (Thousand), 2017 – 2023
- Figure-12: Sweden – Forecast for CGM User (Thousand),2023 – 2028
- Figure-13: Sweden – Self-Monitoring of Blood Glucose (SMBG) Type 1 Diabetes Market (Million US$), 2023 – 2028
- Figure-14: Sweden – Forecast for Self-Monitoring of Blood Glucose (SMBG) Type 1 Diabetes Market (Million US$), 2017 – 2023
- Figure-15: Sweden – Self-Monitoring of Blood Glucose (SMBG) Type 2 Diabetes Market (Million US$), 2023 – 2028
- Figure-16: Sweden – Forecast for Self-Monitoring of Blood Glucose (SMBG) Type 2 Diabetes Market (Million US$), 2017 – 2023
- Figure-17: Sweden – Test Strips Type 1 Diabetes Market (Million US$), 2023 – 2028
- Figure-18: Sweden – Forecast for Test Strips Type 1 Diabetes Market (Million US$), 2017 – 2023
- Figure-19: Sweden – Test Strips Type 2 Diabetes Market (Million US$), 2023 – 2028
- Figure-20: Sweden – Forecast for Test Strips Type 2 Diabetes Market (Million US$), 2017 – 2023
- Figure-21: Sweden – Lancet Type 1 Diabetes Market (Million US$), 2023 – 2028
- Figure-22: Sweden – Forecast for Lancet Type 1 Diabetes Market (Million US$), 2017 – 2023
- Figure-23: Sweden – Lancet Type 2 Diabetes Market (Million US$), 2023 – 2028
- Figure-24: Sweden – Forecast for Lancet Type 2 Diabetes Market (Million US$), 2017 – 2023
- Figure-25: Sweden – Meter Type 1 Diabetes Market (Million US$), 2023 – 2028
- Figure-26: Sweden – Forecast for Meter Type 1 Diabetes Market (Million US$), 2017 – 2023
- Figure-27: Sweden – Meter Type 2 Diabetes Market (Million US$), 2023 – 2028
- Figure-28: Sweden – Forecast for Meter Type 2 Diabetes Market (Million US$), 2017 – 2023
- Figure-29: Sweden – Self-Monitoring of Blood Glucose (SMBG) Type 1 Users (Thousand), 2017 – 2022
- Figure-30: Sweden – Forecast for Self-Monitoring of Blood Glucose (SMBG) Type 1 Users (Thousand), 2023 – 2028
- Figure-31: Sweden – Self-Monitoring of Blood Glucose (SMBG) Type 2 Users (Thousand), 2017 – 2022
- Figure-32: Sweden – Forecast for Self-Monitoring of Blood Glucose (SMBG) Type 2 Users (Thousand), 2023 – 2028
- Figure-33: Sweden – Disposable Insulin Pen Market (Million US$), 2017 – 2023
- Figure-34: Sweden – Forecast for Disposable Insulin Pen Market (Million US$), 2023 – 2028
- Figure-35: Sweden – Reusable Insulin Pen Market (Million US$), 2017 – 2023
- Figure-36: Sweden – Forecast for Reusable Insulin Pen Market (Million US$), 2023 – 2028
- Figure-37: Sweden – Smart Insulin Pen Market (Million US$), 2017 – 2023
- Figure-38: Sweden – Forecast for Smart Insulin Pen Market (Million US$), 2023 – 2028
- Figure-39: Sweden – Disposable Insulin Pen User (Thousand), 2017 – 2022
- Figure-40: Sweden – Forecast for Disposable Insulin Pen User (Thousand), 2023 – 2028
- Figure-41: Sweden – Reusable Insulin Pen User (Thousand), 2017 – 2022
- Figure-42: Sweden – Forecast for Reusable Insulin Pen User (Thousand), 2023 – 2028
- Figure-43: Sweden – Smart Insulin Pen User (Thousand), 2017 – 2022
- Figure-44: Sweden – Forecast for Smart Insulin Pen User (Thousand), 2023 – 2028
- Figure-45: Sweden – Insulin Pump Market for Type 1 Diabetes Market (Million US$), 2017 – 2023
- Figure-46: Sweden – Forecast for Insulin Pump Market for Type 1 Diabetes Market (Million US$), 2023 – 2028
- Figure-47: Sweden – Insulin Pump Market for Type 2 Diabetes Market (Million US$), 2017 – 2023
- Figure-48: Sweden – Forecast for Insulin Pump Market for Type 2 Diabetes Market (Million US$), 2023 – 2028
- Figure-49: Sweden – Insulin Pump Type 1 Users (Thousand), 2017 – 2022
- Figure-50: Sweden – Forecast for Insulin Pump Type 1 Users (Thousand), 2023 – 2028
- Figure-51: Sweden – Insulin Pump Type 2 Users (Thousand), 2017 – 2022
- Figure-52: Sweden – Forecast for Insulin Pump Type 2 Users (Thousand), 2023 – 2028
- Figure-53: B. Braun Melsungen AG – Global Revenue (Billion US$), 2017 – 2022
- Figure-54: B. Braun Melsungen AG – Forecast for Global Revenue (Billion US$), 2023 – 2028
- Figure-55: Eli Lilly – Global Revenue (Billion US$), 2017 – 2022
- Figure-56: Eli Lilly – Forecast for Global Revenue (Billion US$), 2023 – 2028
- Figure-57: Terumo Corporation – Global Revenue (Billion US$), 2017 – 2022
- Figure-58: Terumo Corporation – Forecast for Global Revenue (Billion US$), 2023 – 2028
- Figure-59: BD – Global Revenue (Billion US$), 2017 – 2022
- Figure-60: BD – Forecast for Global Revenue (Billion US$), 2023 – 2028
- Figure-61: Novo Nordisk A/S – Global Revenue (Billion US$), 2017 – 2022
- Figure-62: Novo Nordisk A/S – Forecast for Global Revenue (Billion US$), 2023 – 2028
- Figure-63: Ypsomed AG – Global Revenue (Billion US$), 2017 – 2022
- Figure-64: Ypsomed AG – Forecast for Global Revenue (Billion US$), 2023 – 2028
- Figure-65: Medtronic – Global Revenue (Billion US$), 2017 – 2022
- Figure-66: Medtronic – Forecast for Global Revenue (Billion US$), 2023 – 2028
- Figure-67: Insulet Corporation – Global Revenue (Billion US$), 2017 – 2022
- Figure-68: Insulet Corporation – Forecast for Global Revenue (Billion US$), 2023 – 2028
- Figure-69: DarioHealth Corp – Global Revenue (Billion US$), 2017 – 2022
- Figure-70: DarioHealth Corp – Forecast for Global Revenue (Billion US$), 2023 – 2028
- Figure-71: Abbott Laboratories – Global Revenue (Billion US$), 2017 – 2022
- Figure-72: Abbott Laboratories – Forecast for Global Revenue (Billion US$), 2023 – 2028
- Figure-73: Dexcom Inc – Global Revenue (Billion US$), 2017 – 2022
- Figure-74: Dexcom Inc – Forecast for Global Revenue (Billion US$), 2023 – 2028
- Figure-75: Roche – Global Revenue (Billion US$), 2017 – 2022
- Figure-76: Roche – Forecast for Global Revenue (Billion US$), 2023 – 2028
- Figure-77: Tandem Diabetes Care – Global Revenue (Billion US$), 2017 – 2022
- Figure-78: Tandem Diabetes Care – Forecast for Global Revenue (Billion US$), 2023 – 2028
- List of Tables:
- Table-01: Sweden – Diabetes Market Share by Type (Percent), 2017 – 2022
- Table-02: Sweden – Forecast for Diabetes Market Share by Type (Percent), 2023 – 2028
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.